Scancell (LON:SCLP) Announces Earnings Results

Scancell (LON:SCLP) announced its quarterly earnings results on Thursday. The company reported GBX (0.55) earnings per share for the quarter, Digital Look Earnings reports.

Scancell Trading Down 2.8%

Shares of SCLP stock traded down GBX 0.38 on Thursday, hitting GBX 13. The stock had a trading volume of 2,440,423 shares, compared to its average volume of 2,605,535. The company’s 50 day moving average price is GBX 10.69 and its 200-day moving average price is GBX 10.18. Scancell has a 1 year low of GBX 7.26 and a 1 year high of GBX 14. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The firm has a market capitalization of £134.91 million, a P/E ratio of -10.32 and a beta of 0.35.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.